You are here

Article Text

Article menu
Download PDFPDF
Commentary
Mental health
Medication assisted therapy (MAT) for opioid use disorder (OUD) in youth improves outcomes and saves lives
  1. Patricia O'Malley
  1. Nursing Research, Premier Health Miami Valley Hospital, Dayton, Ohio, USA
  1. Correspondence to Dr Patricia O'Malley, Nursing Research, Premier Health Miami Valley Hospital, Dayton, OH 45409, USA; pomalley{at}premierhealth.com

https://doi.org/10.1136/ebnurs-2018-103053

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Hadland SE, Bagley SM, Rodean J, et al. Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatrics. 2018;172(11):1029–1037. doi:10.1001/jamapediatrics.2018.2143.

    Implications for practice and research

    • Medication assisted therapy (MAT) in opioid use disorder (OUD) is an evidence-based lifesaving intervention and may be underused in youth. More research is needed to uncover barriers to timely MAT intervention.

    • Limited evidence suggests that programme outcomes (retention and attrition) for timely MAT (buprenorphine, naltrexone or methadone) in youth with OUD are favourable. More research in the youth population (under age 18) is needed.

    Context

    Rising morbidity and mortality for adolescents and young adults in the USA is a difficult health issue. Despite recommendations by …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.